Quoin Pharmaceuticals, Ltd.
QNRXHealthcare|Biotechnology|US
$3.65
-0.20 (-5.19%)
DCF Value
$2547.50
Tangible Book / Share
$5.63
Cash / Share
$2.00
About
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Stock Price
-57.4%(1Y)
1M
-19.8%
3M
-23.8%
6M
-38.4%
YTD
-74.7%
1Y
-55.2%
3Y
-97.6%
5Y
-100.0%
Pipeline Summary
4 total trials0
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
Recruiting: 3Active: 1
Active Trials (4)
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
NCT06953466Netherton Syndrome
Phase 2Phase 3Recruiting
Enrollment: 8 participants
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
NCT05521438Netherton Syndrome
Phase 2Phase 3Active
Enrollment: 30 participants
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
NCT07538583Netherton Syndrome
Phase 2Phase 3Recruiting
Enrollment: 16 participants
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
NCT05789056Netherton Syndrome
Phase 2Phase 3Recruiting
Enrollment: 20 participants
Key Facts
Market Cap$7.3M
Employees4 (+33% YoY)
CEOMichael Myers
IPO DateAug 1, 2016
Beta1.75
52-Week Range$3.25 – $23.5
Avg Volume405,926
ExchangeNASDAQ
Websitequoinpharma.com
Ownership
Float71.8%
Shares Outstanding2.0M
Recent Insider Trades
LANGER DENNISOTHER
Aug 27, 20260 shares
Carter Denise P.BUY
Aug 31, 202620,490 shares @ $4.88
Carter Denise P.BUY
Aug 31, 202610,245 shares @ $6.10
Myers MichaelBUY
Aug 31, 202620,490 shares @ $4.88
Myers MichaelBUY
Aug 31, 202610,245 shares @ $6.10
Peers
Recent News
Quoin Pharmaceuticals' Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
Nov 6, 2026 · globenewswire.com
Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Nov 5, 2026 · globenewswire.com
Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Oct 29, 2026 · globenewswire.com
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
Oct 20, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:30 AM